Topin & Associates Selects an Account Supervisor to Manage Teva Neuroscience, Inc. (TEVA)'s Global Brand
12/3/2012 11:25:35 AM
More...
|
Teva Neuroscience, Inc. (TEVA) Will Take 100 Jobs from KC to OP
4/5/2012 7:27:45 AM
More...
|
Teva Neuroscience, Inc. (TEVA) Release: Recently Published Clinical Pharmacology Study Confirms Azilect(R) Selectively Inhibits MAO-B at Approved Doses
6/2/2010 10:29:12 AM
More...
|
BioScrip (BIOS) Commences Patient Enrollment in Teva Neuroscience, Inc. (TEVA) Therapy Optimization in Multiple Sclerosis (Tops MS) Research Study
6/30/2009 9:49:30 AM
More...
|
Teva Neuroscience, Inc. (TEVA): Clinical Pharmacology Study With AZILECT(R) (Rasagiline Tablets) Demonstrated It Does Not Increase Tyramine Sensitivity
6/9/2009 11:25:23 AM
More...
|
Teva Neuroscience, Inc. (TEVA) Release: COPAXONE(R) Significantly Reduced Brain Atrophy and Tissue Loss over Five Years in Treatment-Naive Relapsing-Remitting Multiple Sclerosis Patients
4/18/2008 7:46:56 AM
More...
|
Teva Neuroscience, Inc. (TEVA): Study Showed Patients Using COPAXONE® Had Significantly Lower Risk of Relapse and Lower Medical Costs Compared to Patients Using Rebif® in Relapsing-Remitting Multiple Sclerosis (RRMS)
10/25/2007 9:42:21 AM
More...
|
Teva Neuroscience, Inc. (TEVA): New Long-Term Analysis of Clinical Treatment Outcomes Demonstrated COPAXONE(R) is More Cost Effective Than Tysabri(R) for Treatment of Relapsing-Remitting Multiple Sclerosis
10/25/2007 9:36:41 AM
More...
|
Teva Neuroscience, Inc. (TEVA) Release: International Movement Disorder Specialists Receive New Information About the Use of Once-Daily AZILECT(R) in the Treatment of Parkinson's Disease
6/8/2007 12:58:27 PM
More...
|
Treatment with Teva Neuroscience, Inc. (TEVA)'s COPAXONE(R) Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis
5/4/2007 1:21:33 PM
More...
|
|